Home Resource Center   Consulting Services  DNA Gateway International

PROFILE

DNA Gateway International, Inc. is a provider of business services to biotechnology and pharmaceutical companies. DNA Gateway assists non-US companies with their international efforts entering into the US marketplace. We provide a range of services including U.S. market penetration, strategic alliance navigation, corporate strategy development, business development, accessing U.S. federal funds, navigating legal/IP issues and establishment of U.S. operations. With over 50 years of industry experience, we have a wide range of expertise and an extensive network to draw from. 

With over fifty years of industry experience, our DNA represents the top talent in the industry. Our clients and partners include biotechnology, pharmaceutical, academic and government organizations.

DNA Gateway is a corporate development firm that applies sound research, strategic planning and intelligent solutions to help its clients gain maximum U.S. exposure.  Additionally, we use innovative thinking to accelerate the delivery of safe and effective therapeutics to the U.S. market.

DNA Gateway is strategically located: 
San Francisco- The Birthplace of Biotechnology
Washington D.C.- THE U.S. Center for Drug Approval
Geneva, Switzerland- Easy Access to the EU

Cori Gorman, PhD MBA -- President & CEO
Louis E. "Gene" Burton
Cammie Edwards, PhD
Robert Meister

Cori Gorman, PhD MBA -- President & CEO

Dr. Gorman is an experienced entrepreneur and research scientist with experience in business and drug development aspects of biotechnology industry. Cori has assisted clients in forming over 20 alliances in just one two year period. Dr. Gorman has served on grant review committees that target funds to industry for over seven years. Her clients have successfully obtained over $80 million in US government funds using the strategies and advice of Dr. Gorman.

At Genentech, Dr. Gorman played a key role in the development of a number of marketed products including Kogenate, Activase, Herceptin, Xolair, and Raptiva. She also played a role the early stages of Avastin. Based on her work at Genentech, Cori is also recognized as a pioneer in the development of monoclonal antibody therapeutics and has co-authored 6 INDs.

An experienced entrepreneur, Cori has worked in all aspects of Start-up Company, including raising capital, strategic planning, recruiting scientists, and developing infrastructure. Her contributions were key to enabling Valentis, a gene therapy company, to proceed to a successful IPO. Dr. Gorman has a strong publication and presentation record and is an inventor on several issued patents in the fields of gene expression and delivery and gene therapy.

Dr. Cori Gorman, who is a partner in the firm DNA Bridges, Inc., is a recognized expert in the biotechnology industry having 16 years experience in this field as a research scientist and administrator. Her experience in strategic planning includes work in genomics, functional genomics and microarray screening; vaccine development, including DNA vaccines; tools for gene targeting and persistent gene expression; cancer; cell biology and neurobiology. She has an outstanding record of achievement in basic research and drug development applications in diverse areas including gene therapy, gene expression, and transfer, hormone processing, cell biology, protein transport, and the humanization and production of recombination of proteins. Two projects have resulted in marketed therapeutics and four projects have therapeutics currently in clinical trials. Dr. Gorman has worked for such industry leaders as Genentech while also being experienced in all aspects of a start-up company. She has a strong publication (over 13,000 citations and 6 classic citations) and presentation record. Dr. Gorman developed the CAT assay in 1980 as a postdoctoral fellow in the LMB/NCI. This assay was developed as a sensitive determiner of gene expression and was the industry standard for over more than fifteen years.

Louis E. "Gene" Burton, PhD

Gene Burton, Ph.D., brings more than 22 years of biotechnology industry experience to DNA Bridges/Gateway International, Inc, working in various roles in biotechnology company management, in recombinant drug process and product development and as a seasoned protein chemist. Most recently, he was VP of Product Development and Process Sciences at Receptor BioLogix, Inc., a start up company in the oncology space working in the HER family system of receptors. Prior to the role at Receptor, he spent over 17 years at Genentech, Inc. and 5 years at Bayer Corporation, primarily focused on recombinant protein purification, process design and manufacturing implementation at scale, for pre-IND, IND and BLA drug candidates. He also helped direct the purification design and small-scale production of over 50 different research proteins as well as contributing to the development of two different drug screening programs. He was instrumental in the development program of a drug candidate from its inception to completion of Phase III, acting as the Project Team Leader, CMC team leader or its process development manager, over the course of the project's history.

In addition to his biotechnology experience, Dr. Burton served as an assistant professor and adjunct assistant professor at The Rockefeller University. He has had two postdoctoral experiences: at The Rockefeller with Dr. Stanford Moore, working with ribonuclease inhibitors, and at Stanford University with Dr. Eric Shooter, working with nerve growth factor. He is a member of the ASBMB, Society for Neuroscience and the AAAS, with more than 50 peer-reviewed publications and 5 patent applications or issues. Dr. Burton is a B.S. in Chemistry from Montana State University and a Ph.D. in Biochemistry from Michigan State University.

Cammie Edwards, PhD

Cammie Edwards, PhD has over 15 years of experience in the biopharmaceutical industry. She has successfully assisted clients in obtaining funding, in strategic positioning of their companies and products, in business development activities and in project managements. She has helped early stage life science companies raise over $20 million in both private and government funds. She has worked successfully both with U.S. and international clients on a wide variety of projects, including business, product and clinical development plans, company repositioning in preparation for raising U.S. venture funds and developing strategic international partnerships. Prior to working with DNA Bridges/DNA Gateway, she worked as a scientist in the biopharmaceutical industry. Most recently, at Roche Biosciences, she led a group developing novel small molecule therapies for the treatment of fibrotic diseases. At Genentech and Bristol-Myers Squibb, she worked in the anti-inflammatory programs.

Robert Meister

Robert Meister has more than 10 years of experience in biopharma corporate communications.  Robert provides strategic communications support to pharmaceutical companies, biotechnology companies and third party organizations. His unique hybrid experience leverages expertise in corporate communications, brand strategy, design and information technology.  Robert’s experience comprises a wide range of activities and projects designed to support both corporate and product objectives.  These include branding and message development, FDA panel logistics, media relations, investor relations, patient and professional communications and issues management.  Robert has been involved the development and execution of programs for a wide variety of biopharma companies.  He has also helped many small, start-up companies with their corporate messaging/positioning.

During the course of his career, Robert has been involved in a broad scope of scientific and medical subjects including HIV/AIDS, oncology, stem cells, plasma fractionation and derivatives, skin and tissue rejuvenation and the aesthetics markets and cell line development.